PMS Registry
Company Name
Novartis (Taiwan) Co., Ltd
Protocol Number
Title of Study
A 48-week, observational, longitudinal multicenter study on the effectiveness of 9.5 mg/24 h (10 cm2)Exelon in patients with mild to moderate dementia of the Alzheimer's type
Primary Objective
The primary objective of the study is to evaluate the effectiveness of rivastigmine patch in the management of the various cognitive symptoms in patients with AD in a real-world clinical setting
Number of Sites
Period of Study
From:April 1, 2016 to:December 31, 2018
Number of Patients
IRB Approval Date
March 8, 2016
Publication Plan / Date
December, 2019